Sponsor or institution
Clinical trials and research at CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
As of November 12, 2026, Find a Trial lists 17 clinical trials run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. that are recruiting, at sites in 2 countries (most in China (16), Australia (1)). By phase: Phase 1 (8), Phase 2 (3), Phase 3 (2), Phase 1/2 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 17Clinical trials
- 2Countries
Newest trials
All recruiting trials (17)
-
A new Ammoxetine hydrochloride tablet: bioequivalence and food effect in healthy adults
This study tests a new strength of Ammoxetine hydrochloride enteric-coated tablets to see if it behaves the same as the old formulation and how food affects absorption in healthy adults.
-
Ammoxetine HCl PK test in people with normal vs moderate kidney function
This small, early-phase study tests how ammoxetine hydrochloride behaves in the body when taken daily by people with normal kidney function and those with moderate kidney impairment.
-
Ammoxetine hydrochloride tablets PK and safety in people with different liver function
This study tests how ammoxetine hydrochloride behaves in the body and whether it is safe when taken daily for six days by people with normal liver function and by those with mild or moderate liver impairment.
-
SYH2082 Injection: early-dose safety in adults with overweight or obesity
This early-phase study tests whether a single dose and multiple doses of SYH2082 are safe and well tolerated in healthy adults who are overweight or have obesity.
-
CM326 for moderate to severe COPD
This trial will test whether two doses of CM326 work better than placebo in adults 40–85 with moderate to severe COPD to improve symptoms, reduce exacerbations, and have an acceptable safety profile.
-
Single ascending doses of SYH2085 to test safety and how the body processes the drug
This trial will test single ascending doses of SYH2085 in healthy adults in China to see if the drug is safe, how the body processes it, and whether food changes those effects.
-
Albumin-bound sirolimus combined with different antibody-drug conjugates for advanced solid tumors
This trial will try giving albumin-bound sirolimus together with various antibody-drug conjugates to people with advanced solid tumors to see if the combinations are safe and show anticancer activity.
-
Albumin‑bound sirolimus plus long‑acting octreotide for metastatic gastroenteropancreatic neuroendocrine tumors
This test will see if combining albumin‑bound sirolimus with long‑acting octreotide helps people with unresectable or recurrent non‑functional GEP‑NETs who have poor prognostic factors.
-
Paclitaxel liver-artery infusion plus standard chemo for first-line colorectal liver metastases
This trial will see if giving paclitaxel cationic liposome into the liver artery together with standard first-line chemotherapy (oxaliplatin and capecitabine, with or without bevacizumab) helps people with inoperable colorectal liver metastases.
-
Glumetinib plus albumin-bound docetaxel for advanced stomach/GEJ cancer and other solid tumors
This trial tests whether adding Glumetinib to albumin-bound docetaxel helps adults with advanced gastric or gastroesophageal junction adenocarcinoma and other MET-positive solid tumors.
-
SYS6020 CAR T-cell therapy for refractory generalized myasthenia gravis
This trial will try SYS6020 CAR T-cell infusion in adults with refractory generalized myasthenia gravis to see if it is safe and reduces symptoms.
-
Treatment of advanced solid tumors with paclitaxel cationic liposomes
This study is testing a new way to deliver a cancer drug called paclitaxel to see if it helps people with advanced solid tumors feel better and how safe it is.
-
Assessing a new injection for treating advanced gastrointestinal neuroendocrine tumors
This study is testing a new injection called SYHX2008 to see if it works better than the standard treatment for adults with advanced gastrointestinal neuroendocrine tumors.
-
Comparing DP303c and trastuzumab emtansine for advanced HER2-positive breast cancer
This study is testing a new injection called DP303c to see if it works better than trastuzumab emtansine for people with advanced HER2-positive breast cancer.
-
Comparing two treatments for advanced gastric cancer
This study is testing whether a new version of a cancer drug called Docetaxel can work better than the standard treatment for people with advanced stomach cancer who haven't responded to their first treatment.
-
Evaluating CM310 for treating moderate to severe asthma
This study is testing a new drug called CM310 to see if it can help people with moderate to severe asthma breathe better and feel more comfortable.
-
Combining SKLB1028 with standard chemotherapy for newly diagnosed acute myeloid leukemia
This study is testing if adding a new drug called SKLB1028 to standard chemotherapy helps people with newly diagnosed acute myeloid leukemia feel better and manage side effects.
Quick answers
How many clinical trials run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. are recruiting right now?
17, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in China (16 trials), Australia (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 8, Phase 2: 3, Phase 3: 2, Phase 1/2: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.